Katrine Bosley is a biotechnology entrepreneur. She has been part of the biotech industry for nearly 30 years as a leader in innovative organizations. Most recently, Ms. Bosley was the Chief Executive Officer of Editas Medicine, which is pioneering the advancement of gene editing medicines based on CRISPR. Earlier, she was CEO of Avila Therapeutics and the head of business development for Adnexus Therapeutics.
Ms. Bosley currently serves as Chair of the Emerging Companies Section of BIO – the Biotechnology Innovation Organization, and a Board member of Galapagos NV (EURONEXT and NASDAQ: GLPG), of Genocea Biosciences (NASDAQ: GNCA) and of the Mass Eye and Ear Institute. She has been recognized as one of the 100 Most Creative People in Business by Fast Company, as one of 30 Global Game Changers by Forbes, as Entrepreneur of the Year by the New England Venture Capital Association, and as one of the Top Ten Women in Biotech by FierceBiotech.